Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib Maintenance and Long-Term Extension Study in Crohn's Disease (U-ENDURE)
NCT03345823Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2018
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 49
01
Overview
A Phase 3 trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc.. Started Mar 2018; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03345823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345823.